Sarah Boyce served as President and Chief Executive Officer and a member of the Board of Directors at Avidity Biosciences since October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity was marked by transformative leadership, starting with the company’s successful Series C funding round and IPO. She continued to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three rare neuromuscular disease therapies into clinical development and the expansion of the broad utility of the company’s RNA technology. Her tenure at Avidity culminated with the approximately $12 billion acquisition by Novartis for its neuroscience pipeline and differentiated RNA-delivery platform. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah currently serves as chair of the board of Atrium Therapeutics and as a member of the board of directors at Abcuro and Contineum Therapeutics.
Boyce, Sarah
Sarah Boyce
Director
x
Sarah Boyce
Director
Sarah Boyce served as President and Chief Executive Officer and a member of the Board of Directors at Avidity Biosciences since October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity was marked by transformative leadership, starting with the company’s successful Series C funding round and IPO. She continued to drive the company’s evolution from a research and development entity to a biopharmaceutical company through the advancement of three rare neuromuscular disease therapies into clinical development and the expansion of the broad utility of the company’s RNA technology. Her tenure at Avidity culminated with the approximately $12 billion acquisition by Novartis for its neuroscience pipeline and differentiated RNA-delivery platform. Prior to joining Avidity, Sarah held the position of president and a member of the board of directors of Akcea Therapeutics. She previously held executive roles in business development and global operations for leading life sciences companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. Sarah currently serves as chair of the board of Atrium Therapeutics and as a member of the board of directors at Abcuro and Contineum Therapeutics.
